share_log

Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $8

Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $8

瑞士信贷维持Candel Therapeutics的跑赢大盘,将目标股价下调至8美元
Benzinga Real-time News ·  2022/12/07 04:57

Credit Suisse analyst Judah Frommer maintains Candel Therapeutics (NASDAQ:CADL) with a Outperform and lowers the price target from $10 to $8.

瑞士信贷分析师Judah Frommer维持Candel Treateutics(纳斯达克:CADL)的表现优于预期,并将目标价从10美元下调至8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发